• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: AAN 2015

Use of high-efficacy agents in MS: Updated data from AAN 2015

June 3, 2015  

Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015  

Endovascular trials in ischemic stroke: an update

April 24, 2015  

MS therapies: longer-term results

April 24, 2015  

Anti-LINGO-1 MAb in optic neuritis: RENEW results

April 24, 2015  

Comorbidities common in MS

April 23, 2015  

TARGET trial of intranasal sumatriptan

April 23, 2015  

NEDA-4 – an update

April 23, 2015  

Levodopa-carbidopa intestinal gel: updated GLORIA results

April 22, 2015  

After natalizumab: what are the options?

April 22, 2015  
1
2

Browse by Topic

MS (332)
AD (81)
PD (77)
COVID-19 (58)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (21)
ECTRIMS 2015 (13)
Library (13)
AAN 2015 (11)
ECTRIMS 2019 (10)
ECTRIMS 2021 (10)
ECTRIMS 2014 (10)
DEMENTIA (10)
ECTRIMS 2018 (9)
MS SEQUENCING (9)
ECTRIMS 2013 (9)
AAN 2014 (9)
AAN 2013 (9)
CLINICAL CASES IN MS (8)
PSYCHIATRY (8)
AAN 2019 (7)
ACTRIMS-ECTRIMS 2020 (7)
ECTRIMS 2017 (6)
CHARCOT 2013 (6)
AAN 2021 (6)
ECTRIMS 2022 (6)
ECTRIMS 2016 (5)
CCSVI (5)
BIPOLAR (5)
ANXIETY (5)
AAN 2022 (5)
NeuroSound (4)
BPD (4)
EAN 2015 (4)
AAN 2020 (3)
PAIN (3)
EAN 2022 (3)
AAN 2017 (3)
ENS 2013 (3)
SPECIAL REPORT (2)
EAN 2020 (2)
NEW DRUGS (2)
SLEEP (2)
APA 2014 (2)
AAN 2018 (2)
hATTR (1)
LUMBAR PUNCTURE (1)
LGS (1)
GUIDELINES (1)
ACTRIMS 2022 (1)
SEIZURE (1)
ALS (1)
EAN 2021 (1)
TSC (1)
APA 2016 (1)
INSOMNIA (1)
AAN 2016 (1)
Dravet syndrome (1)
CIDP (1)
CONCUSSION (1)
ADDICTION (1)
WEST NILE (1)
EAN 2019 (1)
EAN 2016 (0)
ECTRIMS 2020 (0)
View all Topics

Popular Posts

  • CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE posted on January 10, 2023
  • The end of MS phenotypes? posted on January 26, 2023
  • MS Awards 2022 – Oddities and Observations posted on December 9, 2022
Copyright 2023 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions